Post Profile

Bristol-Myers to test Opdivo with Nektar drug for several cancers

(Reuters) - Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.
read more


Related Posts

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

News : Yahoo! News: The Upshot

(Reuters) - Pfizer Inc on Tuesday said it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer ...

Nivolumab Becomes First FDA-Approved Checkpoint Blockade for Kidney Cancer

Health : Newswise Medical News

New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo(r), Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)--the most common form of kid...

Bristol-Myers shares are bombing after a failed study — and its biggest rival is surging (BMY, MRK)

Business & Finance : Business Insider: Clusterstock

Shares of Bristol-Myers Squibb were hit hard Friday after news that its blockbuster cancer drug failed a key clinical trial. The drug, called Opdivo, is one of a new set of drugs called immunotherapy. The drug targets the programmed...

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...

Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies

Health : Newswise Medical News

Bristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipili...


Copyright © 2016 Regator, LLC